An Investigational Immuno-Therapy Study of Experimental Medication BMS-986277 Given Alone and in Combination With Nivolumab in Epithelial Cancers

Part of paid clinical trials in Sioux Falls, South Dakota.

Sponsor
Bristol-Myers Squibb
Study ID
NCT03363776
Phase
PHASE1/PHASE2
Status
Terminated

Conditions

  • Cancer

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • BMS-986277 — BIOLOGICAL
    Specified dose on specified days
  • Nivolumab — BIOLOGICAL
    Specified dose on specified days

Study Details

The purpose of this study is to investigate experimental medication BMS-986277 given alone and in combination with Nivolumab in patients with epithelial cancers.

Key Dates

Start date
Dec 6, 2017
Status verified
Nov 2020
Primary completion
Nov 22, 2019
Completion
Nov 22, 2019

Study Design

Enrollment
10 participants (actual)
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Monotherapy
    BMS-986277 administered alone
  • Experimental: Combination Dose Escalation Therapy
    BMS-986277 administered in combination with Nivolumab
  • Experimental: Combination Expansion Therapy
    BMS-986277 monotherapy with option for subsequent Nivolumab therapy

Primary Outcome Measure

Number of Participants With an Adverse Event (AE) [ Time Frame: from first dose to 60 days post last dose, assessed up to February 2020 (approx. 26 months) ]

Locations (1)

FacilityCityStateZIPSite coordinators
Sanford ResearchSioux FallsSouth Dakota57104-

Find similar trials in Sioux Falls, SD

By research site
Sanford Research· Sioux Falls, SD

Related Studies